About this trial
Multiple organ dysfunction syndrome (MODS) after surgical repaired for acute type A aortic dissection (ATAAD) is a life-threatening condition. In this study, patients who undergoing surgical repaired of ATAAD immediately or presenting sever MODS after surgical repaired of acute type A aortic dissection will be treated with umbilical cord-derived mesenchymal stem cell.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients who are diagnosed with ATAAD and received emergency surgery with ascending aortic replacement combined with open placement of triple-branched stent graft
elder than 60 years old
Preoperative PaO2/FiO2 ≥ 400mmHg, platelets ≥ 150*109/L, bilirubin≥ 20μmol/L, no hypotension (without vasoactive drugs), Glasgow Coma Score Scale = 15, creatine ≥110μmol/L
Patients who are diagnosed with ATAAD and received emergency surgery with ascending aortic replacement combined with open placement of triple-branched stent graft
Disqualifiers
• uncontrollable underlying disease life expectancy of less than 4 days history of long-term corticosteroid use during the past 6 months.
The pre-operative computer tomography angiography(CTA) demonstrate the visceral arteries are involved
pre-existing severe disease of any major organs
Trial design
Parallel
Treatments tested in this trial
Exosome of MSC
Biological/VaccineExosome of MSC at a dose of 150mg will be given intravenously to patients once a day for 14 times.
Treatment groups
Trial outcomes
Primary outcomes
survival after intervention
comparing survival ratio in hospital(6 months post-intervention) between groups.
sequential organ failure assessment score
Compare the change of sequential organ failure assessment score between groups. Scores ranged from 0 to 24. The higher the score, the worse the prognosis.
interleukin-6
Compare the change of concentration of interleukin( IL)-6 between groups.
The number of allergic reactions
Allergic reactions are mostly manifested as skin flushing, rash and itching. Severe allergic reactions such as chills, high fever and anaphylactic shock are rare.
Secondary outcomes
the effects on kidney function
the therapeutic effects in the improvement of kidney function, as indicated by Scr level.
the effects on liver function
the therapeutic effects in the improvement of liver function, as indicated by bilirubin levels.
the effects on lung function
the therapeutic effects in the improvement of lung function, as indicated by oxygenation index.
the effects on coagulation function
the therapeutic effects in the improvement of coagulation function, as indicated by blood platelet count.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: